5-氟-2-(三氟甲基)苯硼酸 | 928053-97-8

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氟-2-(三氟甲基)苯硼酸
• 中文别名: 5-氟-2-三氟甲基苯硼酸
• 英文名称: (5-fluoro-2-(trifluoromethyl)phenyl)boronic acid
• 英文别名: 5-Fluoro-2-(trifluoromethyl)phenylboronic acid；[5-fluoro-2-(trifluoromethyl)phenyl]boronic acid
• CAS: 928053-97-8
• 化学式: C₇H₅BF₄O₂
• mdl: MFCD06656275
• 分子量: 207.92
• InChiKey: LBDUHXAQWUKBEB-UHFFFAOYSA-N

物化性质

• 熔点：
  146-150oC
• 溶解度：
  可溶于丙酮（少量）、氯仿（少量）、DMSO（少量）

计算性质

• 辛醇/水分配系数(LogP)：
  2.66
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Fluoro-2-(trifluoromethyl)phenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Fluoro-2-(trifluoromethyl)phenylboronic acid
CAS number: 928053-97-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BF4O2
Molecular weight: 207.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氟-2-(三氟甲基)苯硼酸 在 甲醇 、 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 亚硝酸特丁酯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 碘 、 caesium carbonate 、 magnesium 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 copper(ll) bromide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 28.5h， 生成 8-(5-fluoro-2-(trifluoromethyl)phenyl)-N-(3-(3-methylisothiazol-5-yl)-3-azabicyclo[3.2.1]octan-8-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-amine
  参考文献：
  名称：

  [EN] BRIDGED PIPERIDINE DERIVATIVES
  [FR] DÉRIVÉS DE PIPÉRIDINE PONTÉS

  摘要：

  本发明涉及式(I)的化合物；hetaryl是一个含有1至3个杂原子（O、S或N）的五元杂芳基团；R1是氢、卤素、低碳链烷基、低碳链烷氧基、被卤素取代的低碳链烷基、被卤素取代的S-低碳链烷基或被卤素取代的低碳链烷氧基，或者邻近的两个碳原子可在苯基上形成一个含有-O-CH2-O-的额外环；n为1至5；R2是氢或被卤素取代的低碳链烷基；R3是氢或被卤素取代的低碳链烷基；或其药用酸加合物、消旋混合物、对映体或光学异构体或立体异构体。这些化合物可用于治疗阿尔茨海默病、脑淀粉样血管病、遗传性脑出血伴淀粉样病变的荷兰型（HCHWA-D）、多梗塞性痴呆、拳击性痴呆或唐氏综合征。

  公开号：

  WO2017042114A1

文献信息

• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。
• Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Banner Lester Bruce

  公开号：US20070049632A1

  公开（公告）日：2007-03-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• Pd(II)-Catalyzed Catellani-Type Domino Reaction Utilizing Arylboronic Acids as Substrates
  作者：Guangfa Shi、Changdong Shao、Xiaotian Ma、Yichao Gu、Yanghui Zhang

  DOI：10.1021/acscatal.8b00637

  日期：2018.5.4

  The Catellani reaction provides a facile and efficient method for the synthesis of multifunctionalized arenes. However, the use of Pd(0) catalysts restricts the scope of accessible products. We have developed a Pd(II)-catalyzed, Catellani-type reaction utilizing arylboronic acids as the substrates for the first time. The arylboronic acids can be mono- or dialkylated at the ortho positions with alkyl

  卡泰拉尼反应为合成多功能芳烃提供了一种简便而有效的方法。但是，Pd（0）催化剂的使用限制了可及产品的范围。我们首次开发了以芳基硼酸为底物的Pd（II）催化的Catellani型反应。芳基硼酸可以在邻位用烷基碘化物单烷基或二烷基化，并在ipso位置用烯烃烯烃化，从而产生各种多官能化的芳族化合物。这项工作应开辟新的途径，以开发新的卡特兰尼反应，特别是那些使用新的亲电试剂的反应。
• Development of a Novel Nonpeptidic ¹⁸F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography
  作者：Barbara Wenzel、Jan Mollitor、Winnie Deuther-Conrad、Sladjana Dukic-Stefanovic、Mathias Kranz、Chrysoula Vraka、Rodrigo Teodoro、Robert Günther、Cornelius K. Donat、Friedrich-Alexander Ludwig、Steffen Fischer、Rene Smits、Wolfgang Wadsak、Markus Mitterhauser、Jörg Steinbach、Alexander Hoepping、Peter Brust

  DOI：10.1021/acs.jmedchem.5b01080

  日期：2016.3.10

  With the aim of imaging and quantification of oxytocin receptors (OTRs) in living brain using positron emission tomography (PET), we developed a 18F-labeled small molecule radiotracer and investigated its in vivo pharmacokinetics in mice and pig. [18F]6b (KD = 12.3 nM) was radiolabeled by a two-step procedure using a microwave system with radiochemical yields of 26.9 ± 4.7%. Both organ distribution

  为了使用正电子发射断层扫描（PET）对活体大脑中的催产素受体（OTR）进行成像和定量，我们开发了一种18 F标记的小分子放射性示踪剂，并研究了其在小鼠和猪中的体内药代动力学。[ 18 F] 6b（K D = 12.3 nM）经两步法使用微波系统进行放射性标记，放射化学收率为26.9±4.7％。器官分布和小动物PET研究均显示有限的[ 18 F] 6b脑摄取在老鼠身上（在pi的30分钟时，SUV平均为0.04）。此外，在垂体中观察到显着的放射性吸收（在pi 30分钟时SUV为0.7）。在对一只仔猪进行的动态PET研究中，我们检测到嗅球中[ 18 F] 6b的摄取较高（在pi 30分钟时SUV为0.34），而整个大脑的摄取较低。猪脑切片的体外放射自显影研究表明[ 18 F] 6b与几种脱靶受体的相互作用。
• Valdecoxib <i>vs</i>. borazavaldecoxib: isoxazole BN/CC isosterism as a case study in designing and stabilizing boron heterocycles
  作者：Michele Boghi、Dennis G. Hall

  DOI：10.1039/c8ob00998h

  日期：——

  study on the preparation, hydrolytic stability, and the structural and spectrophotometric properties of 1,2,4,5-oxadiazaboroles is presented by way of a comparison between the NSAID drug valdecoxib (1) and its unprecedented B–N isostere, borazavaldecoxib (2). Knowledge gained from this study was employed in the design of oxadiazaborate salts, a novel class of tetrahedral boron heterocycles displaying

  通过比较NSAID药物valdecoxib（1）和其史无前例的B–N等位基因borazavaldecoxib，对1,2,4,5-恶二氮杂硼酸的制备，水解稳定性以及结构和分光光度特性进行了全面研究。（2）。从这项研究中获得的知识被用于设计草二氮杂硼酸盐，这是一类新型的四面体硼杂环，在水性条件下表现出良好的稳定性，并具有良好的抗真菌和抗菌性能。